Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France.

PURPOSE: The aim of the study was to describe the current rate and determinants of the prescription of antithrombotics in outpatients with permanent atrial fibrillation, with a pre-specified emphasis on the influence of age on the prescription of vitamin K antagonists. METHODS: This was a prospective observational survey in France among 5893 consecutive outpatients with documented permanent atrial fibrillation being seen by 770 physicians from August to December 2002. We recruited physicians from two random lists of general practitioners and cardiologists, respectively, stratified according to their administrative region, from the list of all French private general practitioners and cardiologists. RESULTS: The mean age of patients was 75.8 years. Mean duration since diagnosis of atrial fibrillation was 5.0 years; 31.7% of patients had valvular heart disease and 60.3% hypertension. An antithrombotic was prescribed to 95.5% of patients at the time of consultation. The percentage of patients treated with vitamin K antagonists was 76.4%; it decreased from 86.0% in patients aged 60-70 years to 63.5% in patients aged 80 years or above. On multivariate analysis, high age was a significant predictor (p = 0.001) for the non-prescription of vitamin K antagonists. In patients above 70 years currently receiving an antithrombotic, the probability of prescription of vitamin K antagonists decreased on average by 9.6% per year. CONCLUSIONS: Vitamin K antagonists are administered to most outpatients with permanent atrial fibrillation at high thromboembolic risk seen by French physicians in private practice. However, their use decreases with age.

[Radiofrequency ablation of resistant atrial flutter: a new anatomical approach]. / Ablation par courant de radiofréquence du flutter auriculaire rebelle. Une approche anatomique nouvelle.

Several reports have suggested that radiofrequency ablation could prevent atrial flutter resistant to antiarrhythmic therapy. The usual recommendation is to apply the radiofrequency current in a zone situated between the tricuspid valve and orifice of inferior vena cava. The aim of this study was to assess the efficacy of another site of ablation of flutter extending from the tricuspid valve to the orifice of the coronary sinus, either alone or associated with a site between the coronary sinus and the lateral wall of the right atrium. Twenty patients aged 42 to 78 years (mean : 6 +/- 11 years) were included. Atrial flutter was paroxysmal in 15 patients and chronic in 5 patients. Each patients had documented failure of 1 to 5 antiarrhythmic agents (average 3.1 +/- 1.6). The site of ablation was localised by anatomical criteria alone. During follow-up of 7 +/- 5 months (range 1 to 18 months), 13 patients had no recurrence of atrial flutter after ablation, 5 patients had recurrence and 2 patients had paroxysmal atrial fibrillation alone: the success rate was 15/20 (75%). This study suggests that the zone between the tricuspid valve and coronary sinus may be a site for radiofrequency ablation of atrial flutter. It is valuable alternative to the usually recommended technique.

Transvenous cardioversion of atrial fibrillation using low-energy shocks.

Recent reports have suggested that transvenous cardioversion of atrial fibrillation is feasible using low-energy shocks and a right atrium coronary sinus electrode configuration. We evaluated in a prospective study the efficacy and safety of low-energy internal cardioversion of atrial fibrillation in 104 consecutive patients. Sixty-two patients presented with chronic atrial fibrillation (group I), 16 had paroxysmal atrial fibrillation (group II), and 26 had an induced atrial fibrillation episode (group III). The mean duration of the presenting episode of atrial fibrillation was 9 +/- 19 months for group I, 4 +/- 2 days for group II, and 18 +/- 7 minutes for group III. Atrial defibrillation was performed using two intracardiac catheters: one was placed in the right atrium (cathode) and the other in the coronary sinus or in the left branch of the pulmonary artery (anode). The catheters were connected to a customized external defibrillator capable of delivering 3/3-ms biphasic waveform shocks with a voltage programmable between 10 and 400 volts. The shocks were synchronized to the R wave. Sinus rhythm was restored in 44 of the 62 patients in group I (70%), in 12 of the 16 patients in group II (75%), and in 20 of 26 patients in group III (77%). The mean voltage and energy required for cardioversion were respectively 300 +/- 68 V and 3.5 +/- 1.5 J, for group I, 245 +/- 72 V and 2.0 +/- 0.9 J for group II, and 270 +/- 67 V and 2.6 +/- 1.2 J for group III. The leading-edge voltage required for sinus rhythm restoration was significantly higher (p < 0.05) in the chronic atrial fibrillation group than in the paroxysmal or induced groups. No proarrhythmic effects occurred for the delivered 686 R-wave synchronized shocks. This study of a large group of patients confirms and extends the results of previous reports. Such findings may have clinical implications for elective cardioversion of atrial fibrillation and the development of an implantable atrial defibrillator.

[Cardioversion of atrial fibrillation with low energy internal electric shock]. / Cardioversion par choc électrique interne à basse énergie de la fibrillation auriculaire.

The efficacy and safety of low internal cardioversion for the reduction of atrial fibrillation was assessed prospectively in 104 consecutive patients. Sixty-two patients had chronic atrial fibrillation (Group I). 16 patients had paroxysmal atrial fibrillation (Group II) and 26 patients had induced atrial fibrillation (Group III). The average duration of the current episode of atrial fibrillation was 9 +/- 19 months in Group I, 4 +/- 2 days in Group II and 18 +/- 7 minutes in Group III. Two intracardiac defibrillation catheters were used, one (the cathode) in the right atrium and the other in the coronary sinus or left branch of the pulmonary artery (anode). These catheters were connected to an external defibrillator delivering biphasic 3/3 ms shocks with a voltage which could be programmed from 10 to 400 volts. The shocks were synchronised on the R wave. Sinus rhythm was restored in 44 of the 62 patients in Group I (70%), 12 of the 16 patients in Group II (75%) and 20 of the 26 patients in Group III (77%). The average voltages and energies restoring sinus rhythm were 300 +/- 68 volts and 3.5 +/- 1.5 joules respectively in Group I, 245 +/- 72 volts and 2.0 +/- 2.9 joules in Group II, and 270 +/- 67 volts and 2.6 +/- 1.2 joules in Group III. These results show that the energy required to restore sinus rhythm is significantly greater in patients with chronic atrial fibrillation than in patients with paroxysmal or induced atrial fibrillation. There were no ventricular proarrhythmic effects in the 686 shocks synchronised on the R wave. This study shows that internal cardioversion of atrial fibrillation is feasible with low energies under simple sedation. These results support the concept of an implantable atrial defibrillator.

[Abnormal movements and shaking in geriatrics (author's transl)]. / Mouvements anormaux et agitation en gériatrie.

The authors have experimented tiapride in 37 cases of abnormal movements and 20 cases of shaking anxio depresive origin. The best indication of tiapride corresponds to lingual buccal an facial dyskinesia caused by neuroleptics and senile trembling increased by alcoholism. On the other hand its anxiolytic and anti shaking properties are more limited. Finally in the case of degenerative senile trembling its action is less effective. Tolerance to tiapride seemed to be excellent even at high dose.